Insulin Resistance presentations about Insulin Resistance EB with interest for Insulin Resistance Validating Insulin Resistance content Free registration form / enregistrement gratuit
1
2
  Français - August 16, 2011
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.

CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
  Topic  

Metabolic Syndrome

Metabolic syndrome and the associated increased risk of cardiovascular disease and diabetes is a major concern for healthcare practitioners. Beyond the diagnostic criteria such as outlined by the NCEP ATP III or WHO definitions, numerous other factors are associated with the metabolic syndrome. This section deals with the diagnosis and pathophysiology of the metabolic syndrome, as well as clinical approaches to reducing morbidity and mortality in these patients.

Presentations listing

Lipoprotein Subclasses, Inflammation, and Cardiovascular... - Dr. Robert S. Rosenson
CRP as a Predictor of Hypertension and the Metabolic... - Prof. Leo Niskanen
Transforming the Paradigm for the Metabolic Syndrome - Prof. Steven M. Haffner
Metabolic Syndrome and Insulin Resistance - Prof. Philipp Scherer
Are We Ready to Treat the Metabolic Syndrome? - Dr. Sir George Alberti
Usefulness of Brachial Artery Distensibility in the... - Dr. Meng Cheng Chiang
Does the Metabolic Syndrome Predict Death in Type 2... - Prof. Timothy Davis
Pharmacological Intervention in CVD Risk Factors -... - Prof. Stefano Del Prato
CVD Risk in the Metabolic Syndrome - Dr. Richard W. Nesto
The Influence of Meal and Increment of Postprandial... - Dr. Dorota Zozulinska
Disturbances of Phosphate Metabolism in Patients with... - Dr. Vasilis Tsimihodimos
Prevalence of the Metabolic Syndrome in the City of Beijing... - Dr. Tiemei Zhang
Management of the Metabolic Syndrome: The Evidence Base - Prof. Philip Barter
Origin and Development of the Metabolic Syndrome - Prof. Gaetano Crepaldi
Comparison of the Observed Prevalence of the Metabolic... - Prof. Basil Karamanos
Genetic Prediction of the Metabolic Syndrome: The Botnia... - Dr. Valeriya Lyssenko
Prevalence of the Metabolic Syndrome in Spanish Population - Dr. M.T. Martinez-Larrad
The Metabolic Syndrome - Payers / Insurers Perspective - Prof. Avi Porath
Prevalence of the Metabolic Syndrome, and the Ability of 3... - Prof. Jonathan Shaw
The Metabolic Syndrome -The Clinicians' Point of View - Prof. Gerard Slama
Association of Low Testosterone and Insulin-Like Growth... - Dr. Wing Yee So
IDF Consensus on the Metabolic Syndrome: Definition and... - Dr. Sir George Alberti
Metabolic Syndrome - Does the Diagnosis Make a Difference? - Dr. Lawrence A. Leiter
Dysmetabolic Syndrome, Adverse Pregnancy Outcome and the... - Dr. Joel Ray
Metabolic Syndrome and CHD Risk: Heterogeneity of Risk - Dr. Richard W. Nesto
Introduction - Dr. Richard W. Nesto
Adiponectin and the metabolic syndrome - Dr. Tohru Funahashi
Markers of the metabolic syndrome and CHD risk : evidence... - Prof. Jean-Pierre Després
Markers of the Metabolic Syndrome and CHD Risk: Evidence... - Prof. Jean-Pierre Després
The Metabolic Syndrome in Canada - Dr. Sonia Anand
hiv
 Presentation 

"Lipoprotein Subclasses, Inflammation, and Cardiovascular Risk in the Metabolic Syndrome"

Dr. Robert S. Rosenson (biography)
English - 2006-04-03 - 44 minutes
(52 slides)

Summary :
In this presentation Dr. Rosenson discusses data illustrating the importance of lipoprotein subclasses for cardiovascular risk prediction in individuals with the metabolic syndrome, and the relationship between lipoprotein subclasses, oxidative stress and the inflammatory response.

Which is the best predictor of CHD risk in the metabolic syndrome? According to findings from the...

Learning objectives :
After viewing this presentation the participant will be able to discuss:

- The metabolic pathways that regulate lipoprotein metabolism in insulin resistance
- The importance of lipoprotein subclasses in cardiovascular risk assessment in individuals with the metabolic syndrome
- How changes in lipoprotein subclasses may impact on oxidative stress and elicit the inflammatory response

Bibliographic references :
1. James D. Otvos, PhD; Dorothea Collins, ScD; David S. Freedman, PhD; Irina Shalaurova, MD; Ernst J. Schaefer, MD; Judith R. McNamara, MT; Hanna E. Bloomfield, MD, MPH; Sander J. Robins, MDLow-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial Circulation. 2006;113:1556-1563.

2. Schaefer EJ et al. Circulation.2004;100(Suppl III):777.

3. Sekar Kathiresan, MD; James D. Otvos, PhD; Lisa M. Sullivan, PhD; Michelle J. Keyes, MA; Ernst J. Schaefer, MD; Peter W.F. Wilson, MD; Ralph B. D’Agostino, PhD; Ramachandran S. Vasan, MD; Sander J. Robins, MDIncreased Small Low-Density Lipoprotein Particle Number: A Prominent Feature of the Metabolic Syndrome in the Framingham Heart Study Circulation. 2006;113:20-29.

4. Rosenson RS et al., Diabetes. 2005;54(Suppl 1):A239.

5. Marc Evans, MB BCh; Richard A. Anderson, MB BCh, BSc; John Graham, BSc, PhD; Gethin R. Ellis, MB BCh, BSc; Keith Morris, BSc, PhD; Stephen Davies, MB BCh, MD; Simon K. Jackson, BSc, MSc, PhD; Malcolm J. Lewis, BSc, MB BCh, MD; Michael P. Frenneaux, BSc, MD; Alan Rees, BSc, MD, MB BChCiprofibrate Therapy Improves Endothelial Function and Reduces Postprandial Lipemia and Oxidative Stress in Type 2 Diabetes Mellitus Circulation. 2000;101:1773.

6. Alexandros D. Tselepis; Christine Dentan; Sonia-Athena P. Karabina; M. John Chapman; Ewa NinioPAF-Degrading Acetylhydrolase Is Preferentially Associated With Dense LDL and VHDL-1 in Human Plasma: Catalytic Characteristics and Relation to the Monocyte-Derived Enzyme Arteriosclerosis, Thrombosis, and Vascular Biology. 1995;15:1764-1773.

   


 Presentation 

"CRP as a Predictor of Hypertension and the Metabolic Syndrome"

Prof. Leo Niskanen (biography)
English - 2005-05-18 - 32 minutes
(28 slides)

Summary :
Elevated high-sensitivity C-reactive protein (hs-CRP) levels have been found to be significantly related to an increased risk of coronary heart disease in both men and women (1), but how does low-grade inflammation reflected as elevated hs-CRP relate to hypertension, a major cardiovascular risk factor? In this presentation Prof. Niskanen discusses findings from the Kuopio Ischemic Heart Disease...

Learning objectives :
After viewing this presentation the participant will be able to discuss:

- Data from the WHS and KIHD studies on hs-CRP and the risk of future incidence of hypertension
- Data from the KIHD study on hs-CRP and the risk of developing metabolic syndrome or diabetes
- Evidence for direct proatherogenic effects of CRP
- Conclusions and future directions for research

Bibliographic references :
1. Jennifer K. Pai, M.H.S., Tobias Pischon, M.D., M.P.H., Jing Ma, M.D., Ph.D., JoAnn E. Manson, M.D., Dr.P.H., Susan E. Hankinson, Sc.D., Kaumudi Joshipura, B.D.S., Sc.D., Gary C. Curhan, M.D., Sc.D., Nader Rifai, Ph.D., Carolyn C. Cannuscio, Sc.D., Meir J. Stampfer, M.D., Dr.P.H., and Eric B. Rimm, Sc.D.Inflammatory Markers and the Risk of Coronary Heart Disease in Men and Women NEJM. 2004;351:2599-2610.

2. Claudia U. Chae; Richard T. Lee; Nader Rifai; Paul M. Ridker. Blood Pressure and Inflammation in Apparently Healthy Men Hypertension. 2001;38:399.

3. Gavin J. Blake, MD, MPH, MRCPI; Nader Rifai, PhD; Julie E. Buring, ScD; Paul M Ridker, MD, MPH. Blood Pressure, C-Reactive Protein, and Risk of Future Cardiovascular Events Circulation. 2003;108:2993.

4. Howard D. Sesso, ScD, MPH; Julie E. Buring, ScD; Nader Rifai, PhD; Gavin J. Blake, MD, MPH; J. Michael Gaziano, MD, MPH; Paul M. Ridker, MD, MPH. C-Reactive Protein and the Risk of Developing Hypertension JAMA. 2003;290:2945-2951.

5. Leo Niskanen; David E. Laaksonen; Kristiina Nyyssönen; Kari Punnonen; Veli-Pekka Valkonen; Ricardo Fuentes; Tomi-Pekka Tuomainen; Riitta Salonen; Jukka T. Salonen. Inflammation, Abdominal Obesity, and Smoking as Predictors of Hypertension Hypertension. 2004;44:859.

6. D. E. Laaksonen, L. Niskanen, K. Nyyssönen, K. Punnonen, T.-P. Tuomainen, V.-P. Valkonen, R. Salonen and J. T. Salonen. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men Diabetologia. 2004;47(8):1403 - 1410.

7. Subodh Verma and Edward T. H. Yeh. C-reactive protein and atherothrombosis—Beyond a biomarker: an actual partaker of lesion formation Am J Physiol Regul Integr Comp Physiol 285: R1253-R1256, 2003.

8. Chao-Hung Wang, MD; Shu-Hong Li, MSc; Richard D. Weisel, MD; Paul W.M. Fedak, MD; Aaron S. Dumont, MD; Paul Szmitko, BSc; Ren-Ke Li, MD, PhD; Donald A.G. Mickle, MD; Subodh Verma, MD, PhD. C-Reactive Protein Upregulates Angiotensin Type 1 Receptors in Vascular Smooth Muscle Circulation. 2003;107:1783.

   


 Presentation 

"Transforming the Paradigm for the Metabolic Syndrome"

Prof. Steven M. Haffner (biography)
English - 2005-05-14 - 32 minutes
(32 slides)

Summary :
In this presentation Prof. Haffner talks about the metabolic syndrome and its components in relation to diabetes and CVD risk, and approaches to therapy.

Even before the clinical diagnosis of type 2 diabetes there is an already increased risk of CVD as was seen in the Nurses' Health Study (1). In the San Antonio Heart Study it was possible to look at the heterogeneity of...

Learning objectives :
After viewing this presentation the participant will be able to discuss:

- Differences in risk factor profiles among prediabetic individuals
- Inflammation and the metabolic syndrome
- Diabetes prevention strategies
- Metabolic syndrome as predictor of CVD risk in different populations
- Approaches to therapy for the metabolic syndrome

Bibliographic references :
1. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes. Diabetes Care 25:1129-1134, 2002.

2. Anthony J.G. Hanley, PhD, Ken Williams, MSc, Michael P. Stern, MD and Steven M. Haffner, MD. Homeostasis Model Assessment of Insulin Resistance in Relation to the Incidence of Cardiovascular Disease: The San Antonio Heart Study. Diabetes Care 25:1177-1184, 2002.

3. Andreas Festa, MD; Ralph D’Agostino, Jr, PhD; George Howard, DrPH; Leena Mykkänen, MD, PhD; Russell P. Tracy, PhD; Steven M. Haffner, MD. Chronic Subclinical Inflammation as Part of the Insulin Resistance Syndrome:The Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42.

4. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM; Insulin Resistance Atherosclerosis Study. Elevated Levels of Acute-Phase Proteins and Plasminogen Activator Inhibitor-1 Predict the Development of Type 2 Diabetes: The Insulin Resistance Atherosclerosis Study. Diabetes. 2002 Apr;51(4):1131-7.

5. Hanna-Maaria Lakka, MD, PhD; David E. Laaksonen, MD, MPH; Timo A. Lakka, MD, PhD; Leo K. Niskanen, MD, PhD; Esko Kumpusalo, MD, PhD; Jaakko Tuomilehto, MD, PhD; Jukka T. Salonen, MD, PhD The Metabolic Syndrome and Total and Cardiovascular Disease Mortality in Middle-aged Men. JAMA. 2002;288:2709-2716.

6. Kelly J. Hunt, PhD; Roy G. Resendez, MA; Ken Williams, MS; Steve M. Haffner, MD; Michael P. Stern, MD. National Cholesterol Education Program Versus World Health Organization Metabolic Syndrome in Relation to All-Cause and Cardiovascular Mortality in the San Antonio Heart Study. Circulation. 2004;110:1251-1257.

   


 Presentation 

"Metabolic Syndrome and Insulin Resistance"

Prof. Philipp Scherer (biography)
English - 2005-05-06 - 83 minutes
(47 slides)
(30 slides)
(12 questions)

Summary :
Obesity is an important component of the metabolic syndrome, and in this presentation Prof. Scherer describes the role of adipocyte-derived peptide hormones and their impact on energy metabolism, with a focus on adiponectin, and the contribution of the adipocyte towards systemic inflammation.

Leptin, adiponectin and resistin are peptide hormones that are secreted by adipocytes,...

Learning objectives :
After viewing this presentation the participant will be able to discuss:

- Metabolic effects of adipocyte-secreted peptide hormones;
- Effects of hyperglycaemia-induced reactive oxygen species in the adipocyte;
- Mechanisms of PPAR gamma agonist action in the adipocyte;
- Contributions of the adipocyte to systemic inflammation.

Bibliographic references :
1. R. Retnakaran*, A. J. G. Hanley*, N. Raif, P. W. Connelly, M. Sermer§ and B. Zinman Hypoadiponectinaemia in South Asian women during pregnancy: evidence of ethnic variation in adiponectin concentration Diabetic Medicine. Volume 21 Issue 4 Page 388 - April 2004.

2. Tobias Pischon, MD, MPH; Cynthia J. Girman, DrPH; Gokhan S. Hotamisligil, MD, PhD; Nader Rifai, PhD; Frank B. Hu, MD, PhD; Eric B. Rimm, ScD. Plasma Adiponectin Levels and Risk of Myocardial Infarction in Men JAMA. 2004;291:1730-1737.

   


 Presentation 

"Are We Ready to Treat the Metabolic Syndrome?"

Dr. Sir George Alberti (biography)
English - 2005-04-16 - 28 minutes
(18 slides)

Summary :
It is helpful to (a) know what it is and (b) know what causes it. A working definition is close which will fulfil criterion (a). There is less agreement about criterion (b) with two main schools: those who consider that insulin resistance is undoubtedly causative and those who are more sceptical and consider that the cause is uncertain with some underlying pathophysiological mechanism, such as...

Learning objectives :
After viewing this presentation the participant will be able to discuss:

- The purpose of and prerequisites for treating the metabolic syndrome
- The importance of lifestyle management and the role of pharmacological treatment of components of the metabolic syndrome

   


 Presentation 

"Usefulness of Brachial Artery Distensibility in the Prediction of Coronary Risk Among Asymptomatic Individuals With and Without Metabolic Syndrome"

Dr. Meng Cheng Chiang (biography)
English - 2005-04-16 - 21 minutes
(19 slides)

Summary :
Objective: Previous studies have shown that brachial arterial distensibility (BD) is a measure of arterial stiffness and may be used in risk assessment for cardiovascular disease (CVD). The aim of this study is to explore the predictive value of BD for CVD risk level in asymptomatic individuals with and without Metabolic Syndrome and to seek cardiovascular risk factors influencing BD.

Learning objectives :
After viewing this presentation the participant will be able to discuss:

- The relationship between brachial artery distensibility and cardiovascular risk
- CV risk factors influencing brachial artery distensibility

   


 Presentation 

"Does the Metabolic Syndrome Predict Death in Type 2 Diabetes? The Fremantle Diabetes Study"

Prof. Timothy Davis (biography)
English - 2005-04-15 - 20 minutes
(18 slides)

Summary :
The Fremantle Diabetes Study (FDS) was a prospective, observational study of a representative patient cohort recruited from 1993 to 1996 and followed for at least 5 years. The FDS cohort comprised 1426 patients (63% of all diabetic individuals identified in a catchment area of 120,000 people), and 1294 (91%) had type 2 diabetes. Prospective outcome data were obtained through the Western Australia...

Learning objectives :
After viewing this presentation the participant will be able to discuss results from the Fremantle Diabetes Study relating to:

- Prevalence of metabolic syndrome in type 2 diabetic patients
- Metabolic syndrome as a predictor of all-cause and CHD mortality in type 2 diabetic patients

   


 Presentation 

"Pharmacological Intervention in CVD Risk Factors - Components of the Metabolic Syndrome: Hypertension"

Prof. Stefano Del Prato (biography)
English - 2005-04-15 - 33 minutes
(28 slides)

Summary :
Insulin resistance occurs in many hypertensive patients. Moreover, increased blood pressure levels have been included in the ATP III diagnostic criteria for the Metabolic Syndrome, a condition that is believed to recognize insulin resistance as the background pathogenetic factor. Based on these assumptions, it has been suggested that 1. treatment of hypertension should not aggravate insulin...

Learning objectives :
After viewing this presentation, participants will be able to discuss:
• The importance of hypertension in the definition of the metabolic syndrome
• Improving insulin sensitivity to reduce blood pressure
• Treating hypertension without worsening insulin resistance

Bibliographic references :
Pedrinelli, Roberto; Dell'Omo, Giulia; Penno, Giuseppe; Di Bello, Vitantonio; Giorgi, Davide; Pellegrini, Giovanni; Del Prato, Stefano; Mariani, MarioMicroalbuminuria, a parameter independent of metabolic influences in hypertensive men. Journal of Hypertension. 21(6):1163-1169, June 2003.

Giuseppe Schillaci, Matteo Pirro, Gaetano Vaudo, Fabio Gemelli, Simona Marchesi, Carlo Porcellati and Elmo MannarinoPrognostic value of the metabolic syndrome in essential hypertension Journal of the American College of Cardiology Volume 43, Issue 10 , 19 May 2004, Pages 1817-1822

Jaakko Tuomilehto, M.D., Ph.D., Jaana Lindstrom, M.S., Johan G. Eriksson, M.D., Ph.D., Timo T. Valle, M.D., Helena Hamalainen, M.D., Ph.D., Pirjo Ilanne-Parikka, M.D., Sirkka Keinanen-Kiukaanniemi, M.D., Ph.D., Mauri Laakso, M.D., Anne Louheranta, M.S., Merja Rastas, M.S., Virpi Salminen, M.S., Sirkka Aunola, Ph.D., Zygimantas Cepaitis, Dipl.Eng., Vladislav Moltchanov, Ph.D., Martti Hakumaki, M.D., Ph.D., Marjo Mannelin, M.S., Vesa Martikkala, M.S., Jouko Sundvall, M.S., Matti Uusitupa, M.D., Ph.D., for the Finnish Diabetes Prevention Study Group Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance NEJM Volume 344:1343-1350


Andrea Natali, Stephanie Baldeweg, Elena Toschi, Brunella Capaldo, Daniele Barbaro, Amalia Gastaldelli, John S. Yudkin, and Ele FerranniniVascular Effects of Improving Metabolic Control With Metformin or Rosiglitazone in Type 2 DiabetesDiabetes Care 27: 1349-1357

   


 Presentation 

"CVD Risk in the Metabolic Syndrome"

Dr. Richard W. Nesto (biography)
English - 2005-04-15 - 34 minutes
(24 slides)

Summary :
In this presentation Dr. Nesto gives a general overview of CVD risk in the metabolic syndrome, and discusses specific features of the metabolic syndrome that are strongly associated with risk.

In the U.S. National Health and Nutrition Examination Survey III (NHANES III), metabolic syndrome was associated with history of myocardial infarction and stroke (1), and in NHANES II it was...

Learning objectives :
After viewing this presentation the participant will be able to discuss:

- Increased risk of CHD, CVD and total mortality with the metabolic syndrome
- The importance of high TG and low HDL as determinants of CV risk in the metabolic syndrome
- Hypertension as a more powerful predictor of CV risk in the setting of insulin resistance
- C-reactive protein, metabolic syndrome and CV risk
- Features of high-risk metabolic syndrome patients

Bibliographic references :
1. John K. Ninomiya, MSc; Gilbert L’Italien, PhD; Michael H. Criqui, MD, MPH; Joanna L. Whyte, MS, RD, MSPH; Anthony Gamst, PhD; Roland S. Chen, MD. Association of the Metabolic Syndrome With History of Myocardial Infarction and Stroke in the Third National Health and Nutrition Examination Survey Circulation. 2004;109:42-46.

2. Shaista Malik, MD, MPH; Nathan D. Wong, PhD, MPH; Stanley S. Franklin, MD; Tripthi V. Kamath, PhD; Gilbert J. L’Italien, PhD; Jose R. Pio, BS; G. Rhys Williams, ScD. Impact of the Metabolic Syndrome on Mortality From Coronary Heart Disease, Cardiovascular Disease, and All Causes in United States Adults Circulation. 2004;110:1245-1250.

3. Jørgen Jeppesen, MD; Hans Ole Hein, MD; Poul Suadicani, DD; Finn Gyntelberg, MD. Low Triglycerides–High High-Density Lipoprotein Cholesterol and Risk of Ischemic Heart Disease Arch Intern Med. 2001;161:361-366.

4. Giuseppe Schillaci, Matteo Pirro, Gaetano Vaudo, Fabio Gemelli, Simona Marchesi, Carlo Porcellati and Elmo Mannarino Prognostic value of the metabolic syndrome in essential hypertensionJACC. 19 May 2004, Volume 43, Issue 10 Pages 1817-1822.

5. Frank B. Hu, MD, Meir J. Stampfer, MD, Steven M. Haffner, MD, Caren G. Solomon, MD, Walter C. Willett, MD and JoAnn E. Manson. Impact of the Metabolic Syndrome on Mortality From Coronary Heart Disease, Cardiovascular Disease, and All Causes in United States Adults Diabetes Care 25:1129-1134, 2002.

6. Cuspidi, Cesare; Meani, Stefano; Fusi, Veronica; Severgnini, Barbara; Valerio, Cristiana; Catini, Eleonora; Leonetti, Gastone; Magrini, Fabio; Zanchetti, Alberto. Metabolic syndrome and target organ damage in untreated essential hypertensives.Journal of Hypertension. 22(10):1991-1998, October 2004.

7. Martin K. Rutter, MD; James B. Meigs, MD, MPH; Lisa M. Sullivan, PhD; Ralph B. D’Agostino, Sr, PhD; Peter W.F. Wilson, MD. C-Reactive Protein, the Metabolic Syndrome, and Prediction of Cardiovascular Events in the Framingham Offspring Study Circulation. 2004;110:380-385.

   


 Presentation 

"The Influence of Meal and Increment of Postprandial Glycaemia on Superoxide Production by Polymorphonuclear Neutrophils in Patients with Metabolic Syndrome"

Dr. Dorota Zozulinska (biography)
English - 2005-04-15 - 21 minutes
(19 slides)

Summary :
Inflammatory process plays a crucial role in the development of late diabetic complications and is associated with disturbances between endothelial and inflammatory cells. The peripheral polymorphonuclear neutrophils (PMNs) are one of the main inflammatory cells and seem to significantly influence the damage of endothelium. Mechanisms of injurious effect of activated neutrophils on endothelium...

Learning objectives :
After viewing this presentation, participants will be able to discuss:
• The role of inflammatory processes in the development on metabolic syndrome and diabetes;
• The influence of meal and increment of postprandial glycemia on reactive oxygen species production.

   


 Presentation 

"Disturbances of Phosphate Metabolism in Patients with Metabolic Syndrome"

Dr. Vasilis Tsimihodimos (biography)
English - 2005-04-15 - 24 minutes
(25 slides)

Summary :
Despite the recent advances in the understanding of the consequences of the metabolic syndrome, its pathophysiology remains unclear. It has been proposed that disturbances of phosphate metabolism may contribute to the development of this constellation of cardiovascular risk factors. However, so far there is only little clinical data supporting this hypothesis. The aim of our study was to confirm...

Learning objectives :
After viewing this presentation, participants will be able to discuss:
• The electrolyte abnormalities of the metabolic syndrome
• The possible explanations for these abnormalities
• The potential pathophysiologic role of these electrolyte disturbances

Bibliographic references :
Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002 Jan 16;287(3):356-9.

Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002 Dec 4;288(21):2709-16.

Haglin L. Hypophosphataemia: cause of the disturbed metabolism in the metabolic syndrome. Med Hypotheses. 2001 Jun;56(6):657-63.

   


 Presentation 

"Prevalence of the Metabolic Syndrome in the City of Beijing and Developing a Prediction System for Diabetes in Large Population"

Dr. Tiemei Zhang (biography)
English - 2005-04-15 - 24 minutes
(17 slides)

Summary :
The prevalence of the metabolic syndrome in the city of Beijing was defined by the NCEP-ATPIII(2002) among 15387 adults over 20 years old. The unadjusted prevalence of metabolic syndrome was 9.9% and the age-adjusted prevalence of metabolic syndrome was 7.55% respectively. Using 2000 census data, about 90 million Chinese residents had the metabolic syndrome. The syndrome was more common in the...

Learning objectives :
After viewing this presentation the participant will be able to discuss:

- The prevalence of metabolic syndrome in the city of Beijing
- A prediction system for diabetes based on survey data

   


 Presentation 

"Management of the Metabolic Syndrome: The Evidence Base"

Prof. Philip Barter (biography)
English - 2005-04-14 - 27 minutes
(34 slides)

Summary :
Features of the metabolic syndrome include central adiposity, insulin resistance, dyslipidaemia and mild hypertension. Each of these features contributes to an increased CV risk. Management includes lifestyle measures to promote weight reduction, anti-hypertensive therapy and the use of statins, fibrates and niacin to treat the dyslipidaemia. Insulin sensitizers such as PPAR-gamma agonists may...

Learning objectives :
After viewing this presentation, participants will be able to discuss:
• Which factors predict benefit (reduced cardiovascular risk) from fibrate therapy (Helsinki Heart Study, BIP Study, VA-HIT study)
• Which factors predict benefit from statin therapy (Heart Protection Study)
• What the evidence for fibrate therapy tells us about the metabolic syndrome as a disease entity

Bibliographic references :
Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation. 1995 Oct 1;92(7):1779-85.

Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992 Jan;85(1):37-45.

BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000 Jul 4;102(1):21-7.

Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med. 2002 Dec 9-23;162(22):2597-604.

Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003 Jun 14;361(9374):2005-16.

   


 Presentation 

"Origin and Development of the Metabolic Syndrome"

Prof. Gaetano Crepaldi (biography)
English - 2005-04-14 - 32 minutes
(43 slides)

Summary :
The metabolic syndrome, as a conceptual entity, is a relatively young one. However, the first descriptions of the syndrome and its associated pathology reach as far back as the 17th century. Prof. Gaetano Crepaldi of the University of Padua leads us through the history of the metabolic syndrome, from the first observations of Turp and Morgagni to the accelerated understanding of this “peculiar...

Learning objectives :
After viewing this presentation, participants will be able to discuss:
• The history of the metabolic syndrome
• The different definitions of the metabolic syndrome
• The new consensus on the definitions of the components of the metabolic syndrome
• Recent scientific achievements in the study of the components of the metabolic syndrome
• The results of the Italian Longitudinal Study of Aging (ILSA)
• Future challenges in the study the metabolic syndrome

Bibliographic references :
P. Avogaro, G. Crepaldi, G. Enzi, A. Tiengo. Association of hyperlipemia, diabetes mellitus and mild obesity. Acta Diabetologica Latina, Vol IV, 1967

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 2001; 285: 2486-2497.

Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002 Jan 16;287(3):356-9.

Superko HR. Beyond LDL cholesterol reduction. Circulation. 1996 Nov 15;94(10):2351-4.

Austin MA, Edwards KL. Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Curr Opin Lipidol. 1996 Jun;7(3):167-71.

Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995 Mar 9;332(10):635-41.

Faggin E, Zambon A, Puato M, Deeb SS, Bertocco S, Sartore S, Crepaldi G, Pessina AC, Pauletto P. Association between the --514 C-->T polymorphism of the hepatic lipase gene promoter and unstable carotid plaque in patients with severe carotid artery stenosis. J Am Coll Cardiol. 2002 Sep 18;40(6):1059-66.

   


 Presentation 

"Comparison of the Observed Prevalence of the Metabolic Syndrome with that Expected According to the Random Clustering of its Components. The MGSD Study in Five Mediterranean Countries"

Prof. Basil Karamanos (biography)
English - 2005-04-14 - 16 minutes
(16 slides)

Summary :
AIM: To investigate the prevalence of the Metabolic Syndrome (MS, NCEP criteria) and the various combinations of its components in comparison to the expected frequencies of by chance clustering of these components.

SUBJECTS AND METHODS: We studied 1833 subjects, 20-74 years, in 5 Mediterranean Countries. Blood pressure, waist circumference, fasting glucose and lipids were measured....

Learning objectives :
After viewing this presentation, participants will be able to discuss:
• The goals of the Mediterranean Group for the Study of Diabetes (MGSD) Nutrition Study
• The design of the MGSD Nutrition Study
• The prevalence of the metabolic syndrome (ATP-III definition) and its components among the study population
• How this prevalence compares to the chance clustering of the components

   


 Presentation 

"Genetic Prediction of the Metabolic Syndrome: The Botnia Study"

Dr. Valeriya Lyssenko (biography)
English - 2005-04-14 - 13 minutes
(16 slides)

Summary :
Background and aims: The metabolic syndrome is a cluster of risk factors associated with cardiovascular morbidity and mortality. However, underlying genetic susceptibility to the metabolic syndrome has not been extensively studied. The aim of the study was to evaluate the role of common variants in candidate genes for their ability to predict the metabolic syndrome in a large prospective study...

Learning objectives :
After viewing this presentation, participants will be able to discuss:
• The risk of developing the metabolic syndrome in the BOTNIA population
• Which mutations were associated with the development of the metabolic syndrome
• Which components of the metabolic syndrome (ATP-III) were predictable by the mutations studied

   


 Presentation 

"Prevalence of the Metabolic Syndrome in Spanish Population"

Dr. M.T. Martinez-Larrad (biography)
English - 2005-04-14 - 19 minutes
(23 slides)

Summary :
The MS is a cluster of metabolic abnormalties conferring an increased risk for DM2 and high cardiovascular morbimortality. We investigate the prevalence of the MS in a sample of the Spanish population. A cross-sectional survey in 809 individuals (males 46%), aged 35 - 74 years. A OGTT was performed in all participants. MS was diagnosed according to the criteria issued by NCEP-ATPIII, 3 or more of...

Learning objectives :
- To review data from a cross-sectional population based study to estimate the prevalence of metabolic syndrome in the Spanish population.

   


 Presentation 

"The Metabolic Syndrome - Payers / Insurers Perspective"

Prof. Avi Porath (biography)
English - 2005-04-14 - 27 minutes
(38 slides)

Summary :
Payers and insurers are increasingly recognizing the importance of the metabolic syndrome as a risk factor for cardiovascular (CV) events. Due to limited resources, modern health systems must develop a managerial approach to the condition of metabolic system in the framework of their global CV management priorities. Only recently payers have expanded their management programs to include primary...

Learning objectives :
Managerial formal considerations:
- Magnitude of the problem
- Effectiveness of interventions
- Cost-effectiveness
- Affordability
- Priority setting
Additional considerations
Conclusions

   


 Presentation 

"Prevalence of the Metabolic Syndrome, and the Ability of 3 Definitions to Identify Incident Cases of Diabetes in Australia"

Prof. Jonathan Shaw (biography)
English - 2005-04-14 - 24 minutes
(16 slides)

Summary :
The World Health Organisation (WHO), the (American) National Cholesterol Education Program (NCEP) and the European Group for the study of Insulin Resistance (EGIR) have recently developed independent definitions of the metabolic syndrome (MS). Data from the Australian AusDiab study (1999), and the 5 year follow-up, have been used to calculate the national prevalence of the MS and the ability of...

Learning objectives :
After viewing this presentation, participants will be able to discuss:
• The prevalence of the metabolic syndrome in Australia, using 3 commonly used definitions (WHO, EGIR, ATP-III) as found in the AusDiab Study
• The capacity of the metabolic syndrome to predict incident diabetes
• The degree of insulin resistance associated with each of the 3 definitions

   


 Presentation 

"The Metabolic Syndrome -The Clinicians' Point of View"

Prof. Gerard Slama (biography)
English - 2005-04-14 - 29 minutes
(23 slides)

Summary :
The concept of metabolic syndrome was suspected in the 1950's by a clinician, Jean Vague, in Marseille, France. This remarkable physician noticed that women exhibiting abdominal obesity were more frequently suffering from diabetes, hypertension, and cardiovascular complications. With the thousand of epidemiological and observational studies witch have appeared since, the clinician can only be...

Learning objectives :
After viewing this presentation, participants will be able to discuss:
• The partners in the Metabolic Syndrome Polylogue
• The regulatory oriented/legalistic approach to the management of patients with the metabolic syndrome
• The academic (prudent) approach to the management of patients with the metabolic syndrome
• The activist approach to the management of patients with the metabolic syndrome

   


 Presentation 

"Association of Low Testosterone and Insulin-Like Growth Factor-1 but High C-Reactive Protein with Metabolic Syndrome in Chinese Middle-Aged Men with a Family History of Type 2 Diabetes"

Dr. Wing Yee So (biography)
English - 2005-04-14 - 23 minutes
(15 slides)

Summary :
Aim: Age-related decline in testosterone and insulin-like growth factor-1 (IGF-1) may interact with familial disposition to increase the association with metabolic syndrome (MES).

Methods: We compared clinical characteristics and prevalence of fMES using the WHO criteria with modified definitions of obesity for Asians (BMI³25kg/m2) between 179 middle aged men with family history...

Learning objectives :
After viewing this presentation, participants will be able to discuss:
• The incidence of metabolic syndrome in Chinese men with and without a family history of diabetes
• The association of testosterone, IGF-1 and hs-CRP with the metabolic syndrome
• The metabolic profiles of subjects with/without metabolic syndrome, with/without a family history of diabetes.

   


 Presentation 

"IDF Consensus on the Metabolic Syndrome: Definition and Treatment"

Dr. Sir George Alberti (biography)
English - 2005-04-14 - 38 minutes
(29 slides)

Summary :
The modern era of the "metabolic syndrome" began with the seminal work of Reaven and his Banting Lecture in 1988. He described the association of glucose intolerance, hypertension, dyslipidaemia and obesity and termed it Syndrome X with insulin resistance suggested as the unifying underlying aetiological factor. An explosion of studies and publications followed with the syndrome given a variety...

Learning objectives :
After viewing this presentation the participant will be able to discuss:

- Different names and criteria used to describe the metabolic syndrome
- Conclusions from the 2004 IDF Consensus Meeting on the Metabolic Syndrome

   


 Presentation 

"Metabolic Syndrome - Does the Diagnosis Make a Difference?"

Dr. Lawrence A. Leiter (biography)
English - 2005-01-21 - 43 minutes
(42 slides)
(7 questions)

Summary :
In this presentation Dr. Leiter discusses different aspects of the metabolic syndrome, such as its diagnosis, prevalence, associated cardiovascular risk, pathophysiology and therapeutic approaches.

The metabolic syndrome has been defined in different ways, such as by NCEP ATP III or WHO criteria, and a few studies have compared the prevalence of metabolic syndrome using both of...

Learning objectives :
After viewing this presentation the participant will be able to discuss:

- Studies comparing the prevalence of metabolic syndrome using different definitions
- Metabolic syndrome-associated CVD risk
- The underlying pathophysiology of the metabolic syndrome
- Therapeutic approaches for the metabolic syndrome

Bibliographic references :
1. Earl S. Ford, MD, MPH and Wayne H. Giles, MD, MSC. A Comparison of the Prevalence of the Metabolic Syndrome Using Two Proposed Definitions Diabetes Care 26:575-581, 2003.

2. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K; DECODE Study GroupPrevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and womenArch Intern Med. 2004 May 24;164(10):1066-76.

3. Kelly J. Hunt, PhD; Roy G. Resendez, MA; Ken Williams, MS; Steve M. Haffner, MD; Michael P. Stern, MD National Cholesterol Education Program Versus World Health Organization Metabolic Syndrome in Relation to All-Cause and Cardiovascular Mortality in the San Antonio Heart Study Circulation. 2004;110:1251-1257.

4. Hanna-Maaria Lakka, MD, PhD; David E. Laaksonen, MD, MPH; Timo A. Lakka, MD, PhD; Leo K. Niskanen, MD, PhD; Esko Kumpusalo, MD, PhD; Jaakko Tuomilehto, MD, PhD; Jukka T. Salonen, MD, PhD The Metabolic Syndrome and Total and Cardiovascular Disease Mortality in Middle-aged Men JAMA. 2002;288:2709-2716.

5. Charles M. Alexander, Pamela B. Landsman, Steven M. Teutsch, and Steven M. Haffner. NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older Diabetes 52:1210-1214, 2003.

6. Naveed Sattar, MD; Allan Gaw, MD; Olga Scherbakova, MSc; Ian Ford, PhD; Denis St.J. O’Reilly, MD; Steven M. Haffner, MD; Chris Isles, MD; Peter W. Macfarlane, DSc; Chris J. Packard, DSc; Stuart M. Cobbe, MD; James Shepherd, MD Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study Circulation. 2003;108:414.

7. Zimmet P.Addressing the insulin resistance syndrome: a role for the thiazolidinedionesTrends Cardiovasc Med. 2002 Nov;12(8):354-62.

8. Abhiram Prasad and Arshed A. Quyyumi."Renin-Angiotensin System and Angiotensin Receptor Blockers in the Metabolic Syndrome." Circulation 2004 110: 1507 - 1512.

9. Youlian Liao, PHD, Soonho Kwon, MD, Sara Shaughnessy, MS, RD, Penny Wallace, MS, RN, Amy Hutto, RN, Alicia J. Jenkins, MD, Richard L. Klein, PHD,5 and W. Timothy Garvey, MDCritical Evaluation of Adult Treatment Panel III Criteria in Identifying Insulin Resistance With Dyslipidemia Diabetes Care 27:978-983, 2004.

10. Devaraj S, Rosenson RS, Jialal I.Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status.Endocrinol Metab Clin North Am. 2004 Jun;33(2):431-53.

11. Paul M Ridker, MD; Julie E. Buring, ScD; Nancy R. Cook, ScD; Nader Rifai, PhD C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women Circulation. 2003;107:391.

12. Katherine Esposito, MD; Raffaele Marfella, MD, PhD; Miryam Ciotola, MD; Carmen Di Palo, MD; Francesco Giugliano, MD; Giovanni Giugliano, MD; Massimo D'Armiento, MD; Francesco D'Andrea, MD; Dario Giugliano, MD, PhD. Effect of a Mediterranean-Style Diet on Endothelial Dysfunction and Markers of Vascular Inflammation in the Metabolic Syndrome: A Randomized Trial JAMA. 2004;292:1440-1446.

   


 Presentation 

"Dysmetabolic Syndrome, Adverse Pregnancy Outcome and the Future Risk of Cardiovascular Disease"

Dr. Joel Ray (biography)
English - 2005-01-21 - 32 minutes
(58 slides)
(2 questions)

Summary :
The Dysmetabolic Syndrome also known as Metabolic Syndrome, is known to increase the risk of premature cardiovascular disease. In this presentation Dr. Ray presents evidence showing features of the dysmetabolic syndrome to be associated with adverse pregnancy outcomes such as preeclampsia, poor fetal growth, intrauterine fetal death and preterm birth, and how these conditions in turn affect the...

Learning objectives :
After viewing this presentation the participant will be able to discuss studies showing:

- Adverse (placenta-mediated) outcomes in pregnancy that are associated with features of the dysmetabolic syndrome
- The effect of these adverse outcomes on the risk of future cardiovascular morbidity and mortality

Bibliographic references :
1. C. G. Solomon, W. C. Willett, V. J. Carey, J. Rich-Edwards, D. J. Hunter, G. A. Colditz, M. J. Stampfer, F. E. Speizer, D. Spiegelman and J. E. Manson. A prospective study of pregravid determinants of gestational diabetes mellitusJAMA.1997;278(13):1078.

2. O'Brien TE, Ray JG, Chan WS.
Maternal body mass index and the risk of preeclampsia: a systematic overview.Epidemiology. 2003 May;14(3):368-74.

3. Sven Cnattingius, M.D., Ph.D., Reinhold Bergström, Ph.D., Loren Lipworth, Sc.D., and Michael S. Kramer, M.D.
Prepregnancy Weight and the Risk of Adverse Pregnancy Outcomes NEJM.1998;338:147-152.

4. Tanya K. Sorensen; Michelle A. Williams; I-Min Lee; Edward E. Dashow; Mary Lou Thompson; David A. Luthy Recreational Physical Activity During Pregnancy and Risk of Preeclampsia Hypertension. 2003;41:1273.

5. Myles Wolf, Carl A. Hubel, Chun Lam, Marybeth Sampson, Jeffrey L. Ecker, Roberta B. Ness, Augustine Rajakumar, Ashi Daftary, Alia S. M. Shakir, Ellen W. Seely, James M. Roberts, Vikas P. Sukhatme, S. Ananth Karumanchi and Ravi Thadhani. Preeclampsia and Future Cardiovascular Disease: Potential Role of Altered Angiogenesis and Insulin Resistance JCEM.2004;89(12):6239.

6. Clausen T, Djurovic S, Henriksen T.Dyslipidemia in early second trimester is mainly a feature of women with early onset pre-eclampsia.
BJOG. 2001 Oct;108(10):1081-7.

7. J.G. Ray, R.F. Burrows, E. A. Burrows and M. J. VermeulenMOS HIP: McMaster outcome study of hypertension in pregnancy Early Human Development. Volume 64, Issue 2 , September 2001, Pages 129-143.

8. Gordon CS Smith MD, Jill P Pell MD and David Walsh MScPregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129 290 births The Lancet.
Volume 357, Issue 9273 , 23 June 2001, Pages 2002-2006.

9. Jill P. Pell, Gordon C. S. Smith and David Walsh. Pregnancy Complications and Subsequent Maternal Cerebrovascular Events: A Retrospective Cohort Study of 119,668 Births Am J Epidemiol 2004; 159:336-342.


10. Henrik U Irgens, Lars Reisæter, Lorentz M Irgens and Rolv T LieLong term mortality of mothers and fathers after pre-eclampsia: population based cohort studyBMJ 2001;323:1213-1217.

11. Kestenbaum B, Seliger SL, Easterling TR, Gillen DL, Critchlow CW, Stehman-Breen CO, Schwartz SM. Cardiovascular and thromboembolic events following hypertensive pregnancy.Am J Kidney Dis. 2003 Nov;42(5):982-9.

12. Brenda J Wilson, M Stuart Watson,Gordon J Prescott, Sarah Sunderland, Doris M Campbell,Philip Hannaford and W Cairns S SmithHypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study BMJ 2003;326:845.

13. Leena Haukkamaa MD, Minna Salminen MD, Hannele Laivuori PhD, Hannu Leinonen PhD, Vilho Hiilesmaa PhD and Risto Kaaja PhD. Risk for subsequent coronary artery disease after preeclampsiaThe American Journal of Cardiology. Volume 93, Issue 6 , 15 March 2004, Pages 805-808 .

   


 Presentation 

"Metabolic Syndrome and CHD Risk: Heterogeneity of Risk"

Dr. Richard W. Nesto (biography)
English - 2004-11-08 - 46 minutes
(30 slides)

Summary :
In the U.S. there is a high prevalence of metabolic syndrome (1), and it is of interest to know which patients are at highest risk of cardiovascular disease (CVD), and what factors are driving the higher CVD risk associated with the metabolic syndrome.

In the Rancho Bernardo Study diabetes was found to be a stronger predictor of fatal coronary heart disease (CHD) in women than in...

Learning objectives :
After viewing this presentation the participant will be able to discuss:

- The prevalence of metabolic syndrome in the U.S.
- The differential risk of CHD in diabetic men and women
- The risk of CHD according to the number and type of metabolic syndrome risk factors
- Plasma TG or TG:HDL ratio as indicators of insulin resistance in obese patients

Bibliographic references :
1. Earl S. Ford, MD,MPH; Wayne H. Giles, MD,MSc; William H. Dietz, MD,PhD. Prevalence of the Metabolic Syndrome Among US Adults: Findings From the Third National Health and Nutrition Examination Survey JAMA. 2002;287:356-359.

2. E. L. Barrett-Connor, B. A. Cohn, D. L. Wingard and S. L. Edelstein. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo StudyJAMA. 1991;265:627-631.

3. Oscar C. Marroquin, MD; Kevin E. Kip, PhD; David E. Kelley, MD; B. Delia Johnson, PhD; Leslee J. Shaw, PhD; C. Noel Bairey Merz, MD; Barry L. Sharaf, MD; Carl J. Pepine, MD; George Sopko, MD; Steven E. Reis, MD, for the Women’s Ischemia Syndrome Evaluation Investigators Metabolic Syndrome Modifies the Cardiovascular Risk Associated With Angiographic Coronary Artery Disease in Women: A Report From the Women’s Ischemia Syndrome Evaluation Circulation. 2004;109:714-721.

4. BV Howard, LD Cowan, O Go, TK Welty, DC Robbins and ET Lee.
Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. The Strong Heart StudyDiabetes Care. 1998; Vol 21, Issue 8:1258-1265.

5. Martin K. Rutter, MD; James B. Meigs, MD, MPH; Lisa M. Sullivan, PhD; Ralph B. D’Agostino, Sr, PhD; Peter W.F. Wilson, MD C-Reactive Protein, the Metabolic Syndrome, and Prediction of Cardiovascular Events in the Framingham Offspring Study Circulation. 2004;110:380-385.

6. Shaista Malik, MD, MPH; Nathan D. Wong, PhD, MPH; Stanley S. Franklin, MD; Tripthi V. Kamath, PhD; Gilbert J. L’Italien, PhD; Jose R. Pio, BS; G. Rhys Williams, ScD. Impact of the Metabolic Syndrome on Mortality From Coronary Heart Disease, Cardiovascular Disease, and All Causes in United States Adults Circulation. 2004;110:1245-1250.

7. John K. Ninomiya, MSc; Gilbert L’Italien, PhD; Michael H. Criqui, MD, MPH; Joanna L. Whyte, MS, RD, MSPH; Anthony Gamst, PhD; Roland S. Chen, MD Association of the Metabolic Syndrome With History of Myocardial Infarction and Stroke in the Third National Health and Nutrition Examination Survey Circulation. 2004;109:42-46.

8. Tracey McLaughlin, MD; Fahim Abbasi, MD; Karen Cheal, MPH; James Chu, MD; Cindy Lamendola, MSN; and Gerald Reaven, MD. Use of Metabolic Markers To Identify Overweight Individuals Who Are Insulin ResistantAnn Int Med. 2003;139(10):802-809.

   


 Presentation 

"Introduction"

Dr. Richard W. Nesto (biography)
English - 2004-11-08 - 13 minutes
(9 slides)

Summary :
Dr. Nesto introduces the meeting talking about the burden of metabolic syndrome and the need to prevent type 2 diabetes and CVD in these individuals.

   


 Presentation 

"Adiponectin and the metabolic syndrome"

Dr. Tohru Funahashi (biography)
English - 2003-03-29 - 56 minutes
(55 slides)
(12 questions)

Summary :
The metabolic syndrome, which clusters insulin resistance, hypertension and dyslipidemia, is a common basis of type 2 diabetes and atherosclerotic vascular diseases. Although the molecular link between visceral fat and the metabolic syndrome remains unclear, accumulation of intra-abdominal visceral fat is a major risk of the metabolic syndrome. We discovered a novel adipocyte-specific factor,...

Learning objectives :
The participant will be introduced to adiponectin, a novel adipocyte-specific factor which will represent a new therapeutic target against the metabolic syndrome.

Bibliographic references :
Diabetes 2003 Apr;52(4):910-917
Human Metabolic Syndrome Resulting From Dominant-Negative Mutations in the Nuclear Receptor Peroxisome Proliferator-Activated Receptor-gamma.

Savage DB, Tan GD, Acerini CL, Jebb SA, Agostini M, Gurnell M, Williams RL, Umpleby AM, Thomas EL, Bell JD, Dixon AK, Dunne F, Boiani R, Cinti S, Vidal-Puig A, Karpe F, Chatterjee VK, O'Rahilly S.



Diabetes 2002 Jul;51(7):2325-8
Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome.

Kondo H, Shimomura I, Matsukawa Y, Kumada M, Takahashi M, Matsuda M, Ouchi N, Kihara S, Kawamoto T, Sumitsuji S, Funahashi T, Matsuzawa Y.



Diabetes Care 2002 Feb;25(2):376-80
Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients.

Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY, Chuang LM.



J Clin Endocrinol Metab 2001 Sep;86(9):4321
The genetic basis of plasma variation in adiponectin, a global endophenotype for obesity and the metabolic syndrome.

Comuzzie AG, Funahashi T, Sonnenberg G, Martin LJ, Jacob HJ, Black AE, Maas D, Takahashi M, Kihara S, Tanaka S, Matsuzawa Y, Blangero J, Cohen D, Kissebah A.



Nat Med 2001 Aug;7(8):941-6
The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity.

Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T.

   


 Presentation 

"Markers of the metabolic syndrome and CHD risk : evidence from the Quebec Cardiovascular Study"

Prof. Jean-Pierre Després (biography)
English - 2002-11-23 - 79 minutes
(47 slides)
(9 questions)

Summary :
The prevalence of Type 2 diabetes has substantially increased in North America largely due to the fact that obesity has reached epidemic proportions in our society. Although obesity increases the likelihood of developing Type 2 diabetes, hypertension and coronary heart disease (CHD), not every obese patient is characterized by these complications, emphasizing the heterogeneity of obesity....

Bibliographic references :
1- Insulin resistance and abdominal adiposity in young men with documented malnutrition during the first year of life
Boule NG, Tremblay A, Gonzalez-Barranco J, Aguilar-Salinas CA, Lopez-Alvarenga JC, Despres JP, Bouchard C, Gomez-Perez FJ, Castillo-Martinez L, Rios-Torres JM.
Int J Obes Relat Metab Disord 2003 May;27(5):598-604
http://www.nature.com

2- Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease
Lamarche B, Tchernof A, Mauriege P, Cantin B, Dagenais GR, Lupien PJ, Despres JP
JAMA 1998 Jun 24;279(24):1955-61
http://jama.ama-assn.org/cgi/content/full/279/24/1955

3- Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?
Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Almeras N, Bergeron J, Gaudet D, Tremblay G, Prud'homme D, Nadeau A, Despres JP.
Circulation 2000 Jul 11;102(2):179-84
http://circ.ahajournals.org/cgi/content/full/102/2/179

4- Risk factors associated with obesity: a metabolic perspective]
[Article in French]
Despres JP, Pascot A, Lemieux I.
Ann Endocrinol (Paris) 2000 Dec;61 Suppl 6:31-38
http://www.e2med.com

5- Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.
Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M
N Engl J Med 1998 Jul 23;339(4):229-34
http://content.nejm.org/cgi/content/abstract/339/4/229

6- Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections.
King H, Aubert RE, Herman WH
Diabetes Care 1998 Sep;21(9):1414-31
http://care.diabetesjournals.org

   


 Presentation 

"Markers of the Metabolic Syndrome and CHD Risk: Evidence from the Québec Cardiovascular Study"

Prof. Jean-Pierre Després (biography)
English - 2002-10-28 - 24 minutes
(24 slides)

Summary :
The worldwide increase in the prevalence of Type 2 diabetes represets a tremendous challenge for our health-care system, especially if we consider that this phenomenon is largely explained by the epidemic of obesity. Despite the devastating impact of Type 2 diabetes as a cardiovascular disease risk factor, of equal concern is the fact that the hyperglycemic state of Type 2 diabetes only...

Bibliographic references :
1. Després JP, Lemieux I, Prud’homme D. Treatment of obesity : need to focus on high risk abdominally obese patients. BMJ 2001; 322:716-20
2. Lamarche B, Tchernof A, Mauriège P, et al. Fasting insulin and apolipoprotien B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279;1955-61
3. Lemieux I, Pascot A, Couillard C, et al. A. Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia, hyperapoB, small , dense LDL) in men? Circulation 2000; 102:179-84
4. Lemieux I, Pascot A, Prud’homme D, et al. Elevated C-reactive protein : another compnent of the athero-thrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001; 21:961-7.

   


 Presentation 

"The Metabolic Syndrome in Canada"

Dr. Sonia Anand (biography)
English - 2002-10-28 - 24 minutes
(22 slides)

Summary :
Between 1996-2000, over 1,300 Canadians of varying ancestral origin participated in a study of risk factors for atherosclerosis and CVD (Study of Health Assessment and Risk in Ethnic groups-SHARE). Intriguing differences in their risk factor profiles, as well as the prevalence of metabolic syndrome and CVD were observed. In this talk the highlights of this study will be reviewed, with special...

Bibliographic references :
1. Anand SS, Yusef S, Vuskan CV, et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: The Study of Health Assessment and Risk in Ethinic Groups (SHARE). Lancet 2000; 356(9226):279-84.
2. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 2002; 150(23):2712-8.

   


  Login
  Username :
  Password :
   
  Lost your password?


  Search our website
  Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes.
 




MULTILEARNING - MULTIWEBCAST - MULTIEPOSTER - MULTIEPORTAL

Copyright © 2002-2015 MULTILEARNING Group INC.. All rights reserved.  Disclaimer
Powered by Multiwebcast - webcast services


USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.